3D Bioprinting Market Size, Share & Trends Analysis Report By Technology (Magnetic Levitation, Inkjet-based), By Application (Medical, Dental, Biosensors, Bioinks), By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global 3D bioprinting market size was valued at USD 1.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.8% from 2021 to 2028. The growth of this market is attributed to a limited number of organ donors, and an increasingly aging population with chronic respiratory diseases. Rising R&D investment, technological advancement, and increasing incidence of chronic diseases are other vitally impacting attributes, likely to boost market growth during the forecast period.

As the recent pandemic caused due to coronavirus has taken hold over the globe, even developed countries are witnessing their healthcare systems fatigued and overburdened. Hence, as a reaction to the rising cases of coronavirus, various 3D Bioprinting communities are responding to the worldwide crises by offering their respective skills to ease the burden on the supply chain and governments.

As the cases of COVID-19 are increasing day by day, there has been a shortage of materials for the medical professional as well as for the general public. One of the biggest issues is the lack of availability of test kits for COVID-19. Hence, various 3D bioprinting companies are manufacturing 3D printers and related software on large scale. For example, Formlabs company based in Massachusetts, U.S. is now manufacturing 100,000 nasal swabs for COVID-19 testing each day. Due to the ever-increasing cases of COVID-19, the demand for 3D bioprinters is increasing and the market for 3D bioprinting is expected to witness exponential growth.

The coronavirus pandemic has also accelerated the development of drug and vaccine testing, as scientists are harnessing new technology for safety-testing in patients after preclinical trials are completed. With the ever-increasing cases of COVID-19, the medical world is also facing a shortage of respirators and ventilators. The 3D bioprinting technology is helping in manufacturing respirators and ventilators to overcome the shortage of these devices.

Recently CLECELL, a 3D bioprinting company, has created a respiratory epithelium model using their proprietary 3D printer U-FAB, along with other bioprinting technologies. Respiratory epithelium is a type of tissue that lines most of the respiratory tract. This epithelium acts as a barrier to pathogens and foreign particles. However, it also prevents infection and tissue injury with the help of the mucociliary elevator. Hence, with increasing incidences of demand for this respiratory epithelium model, the market for 3D bioprinting is anticipated to witness growth. Owing to such innovations, the market is expected to witness higher growth over the forecast period.

Many biotherapeutic companies are using 3D bioprinting technology in order to accelerate COVID-19 research. For example, Viscient Biosciences used 3D bioprinting technology to create lung tissue which supports viral infectivity research and helps in searching for effective therapy against SARS-CoV-2, the novel coronavirus which causes COVID-19. The Wyss Institute at Harvard University has designed a fully injection-molded nasopharyngeal swab in collaboration with the healthcare, industrial partners, and other research institutes.

3D bioprinting is witnessing demand on a large scale with the increasing spread of Covid-19. Hence, many pharmaceutical and biopharmaceutical participants are coming forward to help healthcare workers, physicians, and scientists in all possible ways. For example, Stratasys which is one of the leading manufacturers of 3D printers in America has manufactured face shields with the help of a 3D bioprinter. Until March 2020, they shipped 100,000 face shields in the U.S.

Technology Insights

The inkjet-based segment dominated the market for 3D bioprinting and accounted for the largest revenue share of 36.0% in 2020, as it enables the printing of complex living organs or tissues on the culture substrates with the help of biomaterials as bio-inks. The wide adoption of inkjet-based printing in the medical field is contributing to the segment’s growth. This work presents the research trends in inkjet printing as a bio applicable technology, especially in the fields of tissue engineering and drug delivery systems. This segment is anticipated to observe significant growth over the forecast period owing to its increasing demand and higher reliability.

The magnetic levitation segment is projected to expand with the fastest CAGR of 17.0% over the forecast period. The lucrative growth can be attributed to the cost-efficiency associated with the technology. Magnetic levitation technology is expected to solve more than 80.0% of the errors in 3D bioprinting with its advanced features, enhanced speed, and precision. These bioprinters are also used for toxicity screening, vascular muscle printing, and human cell regeneration. For instance, BioAssay has developed a tissue-like structure, with the help of magnetic levitation-based devices. The magnetic levitation based devices are most likely to witness sluggish growth over the forecast period owing to a rapid increase in usage of newer technologies.

Application Type Insights

The medical segment dominated the market for 3D bioprinting and accounted for the largest revenue share of 36.2% in 2020. The segment is anticipated to witness a CAGR of 19.0% over the forecast period. Vast usage of medical pills to cure various chronic diseases is propelling the growth of the market for 3D bioprinting. Moreover, the growing need for medicines and the cost-efficient application of bio-drugs using this technology is further driving the segment. With an increasing number of participants in the pharmaceutical industry, the demand for medical pills is increasing. Millions of people, globally, are regular users of capsules and medicinal pills. Hence, this segment is expected to witness lucrative growth over the forecast period.

The tissue and organ generation sub-segment is expected to witness the fastest CAGR of 19.3% in the market for 3D bioprinting over the forecast period. 3D bioprinting is most widely used to regenerate medicine to address the need for organs and tissue regeneration suitable for transplantation. With the rising incidence of COVID-19 disease, the demand for tissue and organ generation is increasing. Due to this reason, the tissue and organ generation segment is expected to witness exponential growth over the forecast period. The increasing number of COVID -19 cases globally is expected to provide new growth avenues for the key market players. Various players in the market for 3D bioprinting are engaged in developing new techniques that can overcome this pandemic effect and produce a vaccine to treat COVID-19.

Regional Insights

North America dominated the market for 3D bioprinting and accounted for the largest revenue share of 32.4% in 2020. The increasing incorporation of IT in the healthcare industry is estimated to stimulate the growth of the market over the forecast period. As per the World Meter Report 2021, around 23,369,732 active cases of Covid-19 were reported in the U.S. alone until 13 January 2021. There are currently over 50 vaccine candidates under trial. The government is spending more on research and development, in order to come with a vaccine for this condition. Due to this reason, there is an increasing demand for 3D bioprinting as this technology has been reconnoitered for drug testing and organ transplantation.

In Asia Pacific, the market accounted for a revenue share of 23.4% in 2020 and is expected to continue its dominance over the forecast period. Japan and China accounted for the largest revenue share in the region due to the increasing incidence of COVID-19 cases and rising investment of the government in R&D. As per the World Meter Report 2021, around 87,706 active cases of Covid-19 were reported in China until 13 January 2021. Moreover, increasing the mortality rate due to COVID-19 and the shortage of organ donors is further anticipated to drive the market in this region.

Key Companies & Market Share Insights

Key companies are stressing research and development to develop technologically advanced applications to gain a competitive edge. For instance, in November 2019, CELLINK’s developed the most advanced 3D bioprinting device, Bio X6, as well as Lumen X which produces vascular structures. Also, Fluicell Sweden based company has launched a high-resolution bioprinting technology in both 3D and 2D forms, which is named Biopixlar. This 3D bioprinter creates a complex tissue-like structure through which the positioning of individual cells can be controlled. It consists of some novel feature that allows users to control the system.

Companies are engaging in partnerships, mergers, and acquisitions, aiming to strengthen their application portfolio, manufacturing capacities, and provide competitive differentiation. For instance, in November 2019, BASF GmbH acquired Sculpteo which is a 3D printing service provider. This acquisition is anticipated to help BASF to market and establish new industrial 3D printing materials more quickly. Some of the prominent players in the 3D bioprinting market include:

• Envisiontec, Inc.

• Organovo Holdings, Inc.

• Inventia Life Science PTY LTD

• Poietis

• Vivax Bio, LLC

• Allevi

• Cyfuse Biomedical K.K.

• 3D Bioprinting Solutions

• Cellink Global

• Regemat 3D S.L.

3D Bioprinting Market Report Scope 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global 3D bioprinting market report on the basis of technology, application, and region:

• Technology Outlook (Revenue, USD Million, 2016 - 2028)

  • Magnetic Levitation

  • Inkjet-based

  • Syringe-based

  • Laser-based

  • Others

• Application Outlook (Revenue, USD Million, 2016 - 2028)

  • Medical

    • Tissue and organ generation

    • Medical pills

    • Prosthetics and implants

    • Others

  • Dental

  • Biosensors

  • Consumer/Personal Product Testing

  • Bioinks

  • Food and Animal Product

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Columbia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE